HA121-28

N/A

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameHA121-28
Drug Alias NameHA121-28SYHA121-28
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitorsVascular endothelial growth factor receptor inhibitors
TargetsEpidermal growth factor receptor erbB1Vascular endothelial growth factor receptorTyrosine-protein kinase receptor RET
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdCSPC Pharmaceutical Group LtdCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Inactive CompaniesN/A
Active IndicationsMedullary thyroid cancer (MTC)Carcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Inactive IndicationsSolid tumoursBile Duct NeoplasmsBiliary Tract Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A